title: Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy.
abstract: OBJECTIVE
  We sought to evaluate whether statins were associated with a survival benefit and significant attenuation in life-threatening arrhythmias in patients with nonischemic dilated cardiomyopathy.
  
  
  BACKGROUND
  Statins are associated with a reduction in appropriate implantable cardioverter-defibrillator (ICD) therapy in patients with coronary artery disease and improved clinical status in nonischemic dilated cardiomyopathy.
  
  
  METHODS
  The effect of statin use on time to death or resuscitated cardiac arrest and time to arrhythmic sudden death was evaluated in 458 patients enrolled in the DEFINITE (DEFIbrillators in Non-Ischemic cardiomyopathy Treatment Evaluation) study. The effect of statin use on time to first appropriate shock was analyzed only in the 229 patients who were randomized to ICD therapy.
  
  
  RESULTS
  The unadjusted hazard ratio (HR) for death among patients on versus those not on statin therapy was 0.22 (95% confidence interval [CI] 0.09 to 0.55; p = 0.001). When controlled for statin effects, ICD therapy was associated with improved survival (HR 0.61; 95% CI 0.38 to 0.99; p = 0.04). There was one arrhythmic sudden death in the 110 patients receiving statin therapy (0.9%) versus 18 of 348 patients not receiving statins (5.2%; p = 0.04). The unadjusted HR for arrhythmic sudden death among patients on versus those not on statin therapy was 0.16 (95% CI 0.022 to 1.21; p = 0.08). The HR for appropriate shocks among patients on versus those not on statin therapy was 0.78 (95% CI 0.34 to 1.82) after adjustment for baseline differences in the two groups.
  
  
  CONCLUSIONS
  Statin use in the DEFINITE study was associated with a 78% reduction in mortality. This reduction was caused, in part, by a reduction in arrhythmic sudden death. These findings should be confirmed in a prospective, randomized clinical trial.
authors.affiliation: Clinical Trials Unit, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, and the Division of Cardiology, Feinberg School of Medicine, Chicago, Illinois, USA. j-goldberger@northwestern.edu
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Goldberger
authors.forename: Haris
authors.initials: H
authors.lastname: Subacius
authors.forename: Andi
authors.initials: A
authors.lastname: Schaechter
authors.forename: Adam
authors.initials: A
authors.lastname: Howard
authors.forename: Ronald
authors.initials: R
authors.lastname: Berger
authors.forename: Alaa
authors.initials: A
authors.lastname: Shalaby
authors.forename: Joseph
authors.initials: J
authors.lastname: Levine
authors.forename: Alan H
authors.initials: AH
authors.lastname: Kadish
mesh_terms: D000368:Aged; D001145:Arrhythmias, Cardiac / Q000209:etiology* / Q000401:mortality / Q000628:therapy; D002311:Cardiomyopathy, Dilated / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D016757:Death, Sudden, Cardiac / Q000453:epidemiology; D017147:Defibrillators, Implantable; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors